{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:11:08Z","timestamp":1793772668443,"version":"4.6.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11845-023-03388-5","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T09:02:17Z","timestamp":1683363737000},"page":"2801-2808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effects of myo-inositol vs. metformin on hormonal and metabolic parameters in women with PCOS: a meta-analysis"],"prefix":"10.1007","volume":"192","author":[{"given":"Kaneez","family":"Fatima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Faheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alishba","family":"Adnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Sarmad","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsa","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Mohiuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anosha","family":"Sajid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2079-148X","authenticated-orcid":false,"given":"Sidhant","family":"Ochani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,6]]},"reference":[{"key":"3388_CR1","doi-asserted-by":"publisher","first-page":"49109","DOI":"10.1155\/2007\/49109","volume":"2007","author":"U Unluturk","year":"2007","unstructured":"Unluturk U, Harmanci A, Kocaefe C, Yildiz BO (2007) The genetic basis of the polycystic ovary syndrome: a literature review including discussion of PPAR-gamma. PPAR Res 2007:49109. https:\/\/doi.org\/10.1155\/2007\/49109. (PMID: 17389770; PMCID: PMC1820621)","journal-title":"PPAR Res"},{"key":"3388_CR2","doi-asserted-by":"publisher","unstructured":"Rao M, Broughton KS, LeMieux MJ (2020) PhDb Cross-sectional study on the knowledge and prevalence of pcos at a multiethnic university, Prog Prevent Med p e0028. https:\/\/doi.org\/10.1097\/pp9.0000000000000028","DOI":"10.1097\/pp9.0000000000000028"},{"key":"3388_CR3","doi-asserted-by":"publisher","unstructured":"Fryk E, Olausson J, Mossberg K et al (2021) Hyperinsulinemia and insulin resistance in the obese may develop as part of a homeostatic response to elevated free fatty acids: A mechanistic case-control and a population-based cohort study. EBioMedicine 65:103264. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103264. (Epub 2021 Mar 9. PMID: 33712379; PMCID: PMC7992078)","DOI":"10.1016\/j.ebiom.2021.103264"},{"key":"3388_CR4","doi-asserted-by":"publisher","unstructured":"Moran LJ, Hutchison SK, Norman RJ, Teede HJ (2011) Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev (2):CD007506. https:\/\/doi.org\/10.1002\/14651858.CD007506.pub2. (Update in: Cochrane Database Syst Rev. 2011;(7):CD007506. PMID: 21328294)","DOI":"10.1002\/14651858.CD007506.pub2"},{"issue":"10","key":"3388_CR5","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1517\/13543784.13.10.1295","volume":"13","author":"BO Yildiz","year":"2004","unstructured":"Yildiz BO (2004) Recent advances in the treatment of polycystic ovary syndrome. Expert Opin Investig Drug 13(10):1295\u20131305. https:\/\/doi.org\/10.1517\/13543784.13.10.1295. (PMID: 15461558)","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"3388_CR6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","volume":"43","author":"EM Velazquez","year":"1994","unstructured":"Velazquez EM, Mendoza S, Hamer T et al (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43(5):647\u2013654. https:\/\/doi.org\/10.1016\/0026-0495(94)90209-7. (PMID: 8177055)","journal-title":"Metabolism"},{"issue":"1","key":"3388_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1056\/NEJMct0707092","volume":"358","author":"JE Nestler","year":"2008","unstructured":"Nestler JE (2008) Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 358(1):47\u201354. https:\/\/doi.org\/10.1056\/NEJMct0707092. (PMID: 18172174)","journal-title":"N Engl J Med"},{"issue":"1","key":"3388_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/08998280.2015.11929178","volume":"28","author":"B Blough","year":"2015","unstructured":"Blough B, Moreland A, Mora A Jr (2015) Metformin-induced lactic acidosis with emphasis on the anion gap. Proc (Bayl Univ Med Cent) 28(1):31\u201333. https:\/\/doi.org\/10.1080\/08998280.2015.11929178. (PMID: 25552792; PMCID: PMC4264704)","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"8","key":"3388_CR9","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1530\/EC-17-0243","volume":"6","author":"V Unfer","year":"2017","unstructured":"Unfer V, Facchinetti F, Orr\u00f9 B et al (2017) Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect 6(8):647\u2013658. https:\/\/doi.org\/10.1530\/EC-17-0243. (PMID: 29042448; PMCID: PMC5655679)","journal-title":"Endocr Connect"},{"key":"3388_CR10","doi-asserted-by":"publisher","unstructured":"Regidor PA, Schindler AE, Lesoine B, Druckman R (2018) Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm Mol Biol Clin Investig 34(2). https:\/\/doi.org\/10.1515\/hmbci-2017-0067. (PMID: 29498933)","DOI":"10.1515\/hmbci-2017-0067"},{"key":"3388_CR11","unstructured":"Le Donne M, Alibrandi A, Giarrusso R et al (2012) Dieta, metformina e inositolo in donne sovrappeso e obese con sindrome dell'ovaio policistico: effetti sulla composizione corporea [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]. Minerva Ginecol 64(1):23\u20139. Italian. (PMID: 22334228)"},{"key":"3388_CR12","unstructured":"International evidence-based guideline for the assessment and management of polycystic ovary syndrome (2018) Monash University, Melbourne, Australia"},{"issue":"3","key":"3388_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/09513590.2018.1540578","volume":"35","author":"F Facchinetti","year":"2019","unstructured":"Facchinetti F, Orr\u00f9 B, Grandi G, Unfer V (2019) Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol Endocrinol 35(3):198\u2013206. https:\/\/doi.org\/10.1080\/09513590.2018.1540578. (Epub 2019 Jan 7 PMID: 30614282)","journal-title":"Gynecol Endocrinol"},{"key":"3388_CR14","doi-asserted-by":"publisher","unstructured":"Page MJ, Moher D, Bossuyt PM et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160. Published 2021 Mar 29. https:\/\/doi.org\/10.1136\/bmj.n160","DOI":"10.1136\/bmj.n160"},{"key":"3388_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"3388_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926","journal-title":"BMJ"},{"key":"3388_CR17","unstructured":"Higgins JPT, Thomas J, Chandler J et al (Eds.) (22019) Cochrane Handbook for Systematic Reviews of Interventions, 2nd ed.; Wiley Blackwell: Hoboken, NJ, USA"},{"key":"3388_CR18","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.18203\/2320-1770.ijrcog20171563","volume":"6","author":"K Chirania","year":"2017","unstructured":"Chirania K, Misa S, Behera S (2017) A randomised clinical trial comparing myoinositol and metformin in PCOS. Int J Reprod Contracept Obstet Gyne-col 6:1814\u20131820","journal-title":"Int J Reprod Contracept Obstet Gyne-col"},{"key":"3388_CR19","unstructured":"Angik R, Jajoo SS, Hariharan C, Chimote A (2017) A comparative study of metabolic and hormonal effects of myoinositol vs. metformin in women with polycystic ovary syndrome: a randomised controlled trial. Int J Reprod Contracept Obstet Gynecol 4:189\u2013194"},{"key":"3388_CR20","first-page":"1664","volume":"8","author":"J Nehra","year":"2017","unstructured":"Nehra J, Kaushal J, Singhal SR, Gehlaut V (2017) A comparative study of myo inositol versus Metformin on biochemical profile in polycystic ovarian syndrome in women. Int J Pharm Sci Res 8:1664\u20131670","journal-title":"Int J Pharm Sci Res"},{"issue":"1","key":"3388_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/09513590.2016.1236078","volume":"33","author":"F Fruzzetti","year":"2017","unstructured":"Fruzzetti F, Perini D, Russo M et al (2017) Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol 33(1):39\u201342. https:\/\/doi.org\/10.1080\/09513590.2016.1236078. (Epub 2016 Nov 3 PMID: 27808588)","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"3388_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3109\/09513590903366996","volume":"26","author":"E Raffone","year":"2010","unstructured":"Raffone E, Rizzo P, Benedetto V (2010) Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol 26(4):275\u2013280. https:\/\/doi.org\/10.3109\/09513590903366996. (PMID: 20222840)","journal-title":"Gynecol Endocrinol"},{"issue":"5","key":"3388_CR23","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/cen.13304","volume":"86","author":"V Tagliaferri","year":"2017","unstructured":"Tagliaferri V, Romualdi D, Immediata V et al (2017) Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clin Endocrinol (Oxf) 86(5):725\u2013730. https:\/\/doi.org\/10.1111\/cen.13304. (Epub 2017 Feb 10 PMID: 28092404)","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"3388_CR24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1080\/09513590.2018.1540570","volume":"35","author":"M Shokrpour","year":"2019","unstructured":"Shokrpour M, Foroozanfard F, Afshar Ebrahimi F et al (2019) Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. Gynecol Endocrinol 35(5):406\u2013411. https:\/\/doi.org\/10.1080\/09513590.2018.1540570. (Epub 2019 Jan 4 PMID: 30608001)","journal-title":"Gynecol Endocrinol"},{"key":"3388_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4172\/2167-0943.1000127","volume":"2","author":"VD Leo","year":"2013","unstructured":"Leo VD, Musacchio MC, Cappelli V et al (2013) A combined treatment with myo-inositol and monacolin k improve the androgen and lipid profiles of insulin-resistant PCOS patients. J Metabolic Synd 2:127. https:\/\/doi.org\/10.4172\/2167-0943.1000127","journal-title":"J Metabolic Synd"},{"key":"3388_CR26","doi-asserted-by":"publisher","unstructured":"Azizi Kutenaei M, Hosseini Teshnizi S, Ghaemmaghami P et al (2021) The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 25(7):3105\u20133115. https:\/\/doi.org\/10.26355\/eurrev_202104_25565. (PMID: 33877679)","DOI":"10.26355\/eurrev_202104_25565"},{"issue":"8","key":"3388_CR27","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1007\/s43032-022-00933-y","volume":"29","author":"H Jethaliya","year":"2022","unstructured":"Jethaliya H, Gajjar N, Patel V et al (2022) Efficacy of myo-inositol on anthropometric, metabolic, and endocrine outcomes in PCOS patients: a meta-analysis of randomized controlled trial. Reprod Sci 29(8):2282\u20132298. https:\/\/doi.org\/10.1007\/s43032-022-00933-y. (Epub 2022 Apr 27 PMID: 35477841)","journal-title":"Reprod Sci"},{"key":"3388_CR28","doi-asserted-by":"publisher","unstructured":"Teede HJ, Misso ML, Costello MF et al (2018) Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 110(3):364\u2013379. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.05.004. (Epub 2018 Jul 19. PMID: 30033227; PMCID: PMC6939856)","DOI":"10.1016\/j.fertnstert.2018.05.004"},{"issue":"3","key":"3388_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrendo.2013.256","volume":"10","author":"I Pernicova","year":"2014","unstructured":"Pernicova I, Korbonits M (2014) Metformin\u2013mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10(3):143\u2013156. https:\/\/doi.org\/10.1038\/nrendo.2013.256. (Epub 2014 Jan 7 PMID: 24393785)","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"3388_CR30","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1210\/jc.2002-021394","volume":"88","author":"JE Gunton","year":"2003","unstructured":"Gunton JE, Delhanty PJ, Takahashi S, Baxter RC (2003) Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab 88(3):1323\u20131332. https:\/\/doi.org\/10.1210\/jc.2002-021394. (Erratum. In: J Clin Endocrinol Metab 2004 Jan; 89(1): 434. PMID: 12629126)","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"3388_CR31","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1053\/meta.2001.24192","volume":"50","author":"CJ Glueck","year":"2001","unstructured":"Glueck CJ, Fontaine RN, Wang P et al (2001) Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 50(7):856\u2013861. https:\/\/doi.org\/10.1053\/meta.2001.24192. (PMID: 11436194)","journal-title":"Metabolism"},{"issue":"2","key":"3388_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.amjmed.2007.09.016","volume":"121","author":"SR Salpeter","year":"2008","unstructured":"Salpeter SR, Buckley NS, Kahn JA, Salpeter EE (2008) Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 121(2):149-157.e2. https:\/\/doi.org\/10.1016\/j.amjmed.2007.09.016. (PMID: 18261504)","journal-title":"Am J Med"},{"issue":"1","key":"3388_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1046\/j.1463-1326.2002.00181.x","volume":"4","author":"A Gokcel","year":"2002","unstructured":"Gokcel A, Gumurdulu Y, Karakose H et al (2002) Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 4(1):49\u201355. https:\/\/doi.org\/10.1046\/j.1463-1326.2002.00181.x. (PMID: 11874442)","journal-title":"Diabetes Obes Metab"},{"key":"3388_CR34","doi-asserted-by":"publisher","unstructured":"Andrews M, Soto N, Arredondo M (2012) Efecto de metformina sobre la expresi\u00f3n del factor de necrosis tumoral-\u03b1, los receptores Toll-like 2\/4 y la PCR ultra sensible en sujetos obesos con diabetes tipo 2 [Effect of metformin on the expression of tumor necrosis factor-\u03b1, Toll like receptors 2\/4 and C reactive protein in obese type-2 diabetic patients]. Rev Med Chil 140(11):1377\u201382. Spanish. https:\/\/doi.org\/10.4067\/S0034-98872012001100001. (PMID: 23677182)","DOI":"10.4067\/S0034-98872012001100001"},{"issue":"12","key":"3388_CR35","doi-asserted-by":"publisher","first-page":"8005","DOI":"10.4049\/jimmunol.0803563","volume":"182","author":"N Nath","year":"2009","unstructured":"Nath N, Khan M, Paintlia MK et al (2009) Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol 182(12):8005\u20138014. https:\/\/doi.org\/10.4049\/jimmunol.0803563. (Erratum. In: J Immunol 2009 Sep 1;183(5): 3551. Singh, Inderjit [added]. PMID: 19494326; PMCID: PMC2965405)","journal-title":"J Immunol"},{"issue":"4","key":"3388_CR36","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.pcd.2017.03.006","volume":"11","author":"M Shani","year":"2017","unstructured":"Shani M, Lustman A, Vinker S (2017) Diabetes medication persistence, different medications have different persistence rates. Prim Care Diabetes 11(4):360\u2013364. https:\/\/doi.org\/10.1016\/j.pcd.2017.03.006. (Epub 2017 Apr 15 PMID: 28420583)","journal-title":"Prim Care Diabetes"},{"issue":"4","key":"3388_CR37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3945\/an.117.015560","volume":"8","author":"A Lenhart","year":"2017","unstructured":"Lenhart A, Chey WD (2017) A systematic review of the effects of polyols on gastrointestinal health and irritable bowel syndrome. Adv Nutr 8(4):587\u2013596. https:\/\/doi.org\/10.3945\/an.117.015560. (PMID: 28710145; PMCID: PMC5508768)","journal-title":"Adv Nutr"},{"key":"3388_CR38","doi-asserted-by":"publisher","unstructured":"Eagle H, Oyama VI, Levy M, Freeman A (1956) Myo-inositol as an essential growth factor for normal and malignant human cells in tissue culture. Science 123(3202):845\u20137. https:\/\/doi.org\/10.1126\/science.123.3202.845-a. (PMID: 13324100)","DOI":"10.1126\/science.123.3202.845-a"},{"issue":"5460","key":"3388_CR39","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1126\/science.287.5460.2026","volume":"287","author":"AR Odom","year":"2000","unstructured":"Odom AR, Stahlberg A, Wente SR, York JD (2000) A role for nuclear inositol 1,4,5-trisphosphate kinase in transcriptional control. Science 287(5460):2026\u20132029. https:\/\/doi.org\/10.1126\/science.287.5460.2026. (PMID: 10720331)","journal-title":"Science"},{"key":"3388_CR40","unstructured":"Chang HHG (2011) Mechanisms underlying the abnormal inositol metabolisms in diabetes mellitus. Thesis, ResearchSpace@Auckland"},{"issue":"1","key":"3388_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/15604280212528","volume":"3","author":"J Larner","year":"2002","unstructured":"Larner J (2002) D-chiro-inositol\u2013its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 3(1):47\u201360. https:\/\/doi.org\/10.1080\/15604280212528. (PMID: 11900279; PMCID: PMC2478565)","journal-title":"Int J Exp Diabetes Res"},{"issue":"6","key":"3388_CR42","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.bbamcr.2008.10.005","volume":"1793","author":"MJ Berridge","year":"2009","unstructured":"Berridge MJ (2009) Inositol trisphosphate and calcium signalling mechanisms. Biochim Biophys Acta 1793(6):933\u2013940. https:\/\/doi.org\/10.1016\/j.bbamcr.2008.10.005. (Epub 2008 Oct 29 PMID: 19010359)","journal-title":"Biochim Biophys Acta"},{"issue":"5424","key":"3388_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1126\/science.285.5424.96","volume":"285","author":"JD York","year":"1999","unstructured":"York JD, Odom AR, Murphy R et al (1999) A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. Science 285(5424):96\u2013100. https:\/\/doi.org\/10.1126\/science.285.5424.96. (PMID: 10390371)","journal-title":"Science"},{"issue":"6","key":"3388_CR44","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/09513590.2018.1549656","volume":"35","author":"A Agrawal","year":"2019","unstructured":"Agrawal A, Mahey R, Kachhawa G et al (2019) Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecol Endocrinol 35(6):511\u2013514. https:\/\/doi.org\/10.1080\/09513590.2018.1549656. (Epub 2019 Jan 7 PMID: 30614289)","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"3388_CR45","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S0006-291X(02)00313-3","volume":"293","author":"TH Sun","year":"2002","unstructured":"Sun TH, Heimark DB, Nguygen T et al (2002) Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun 293(3):1092\u20131098. https:\/\/doi.org\/10.1016\/S0006-291X(02)00313-3. (PMID: 12051772)","journal-title":"Biochem Biophys Res Commun"},{"key":"3388_CR46","doi-asserted-by":"publisher","unstructured":"Dinicola S, Minini M, Unfer V et al (2017) Nutritional and acquired deficiencies in inositol bioavailability. correlations with metabolic disorders. Int J Mol Sci 18. https:\/\/doi.org\/10.3390\/ijms18102187. (Epub ahead of print: 20 Oct 2017)","DOI":"10.3390\/ijms18102187"},{"key":"3388_CR47","doi-asserted-by":"publisher","unstructured":"DiNicolantonio JJ, O\u2019Keefe JH (2022) Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes. Open Heart 9(1):e001989. https:\/\/doi.org\/10.1136\/openhrt-2022-001989. (PMID: 35236761; PMCID: PMC8896029)","DOI":"10.1136\/openhrt-2022-001989"},{"issue":"8","key":"3388_CR48","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1530\/EC-17-0243","volume":"6","author":"V Unfer","year":"2017","unstructured":"Unfer V, Facchinetti F, Orr\u00f9 B et al (2017) Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect 6(8):647\u2013658. https:\/\/doi.org\/10.1530\/EC-17-0243. (PMID: 29042448; PMCID: PMC5655679)","journal-title":"Endocr Connect"},{"issue":"3","key":"3388_CR49","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/1471-0528.14754","volume":"125","author":"J Pundir","year":"2018","unstructured":"Pundir J, Psaroudakis D, Savnur P et al (2018) Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG 125(3):299\u2013308. https:\/\/doi.org\/10.1111\/1471-0528.14754. (Epub 2017 Jul 14 PMID: 28544572)","journal-title":"BJOG"},{"issue":"6","key":"3388_CR50","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.rbmo.2016.08.024","volume":"33","author":"AD Genazzani","year":"2016","unstructured":"Genazzani AD (2016) Inositol as putative integrative treatment for PCOS. Reprod Biomed Online 33(6):770\u2013780. https:\/\/doi.org\/10.1016\/j.rbmo.2016.08.024. (Epub 2016 Sep 16 PMID: 27717596)","journal-title":"Reprod Biomed Online"},{"issue":"10","key":"3388_CR51","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/aogs.13395","volume":"97","author":"T Tanbo","year":"2018","unstructured":"Tanbo T, Mellembakken J, Bjercke S et al (2018) Ovulation induction in polycystic ovary syndrome. Acta Obstet Gynecol Scand 97(10):1162\u20131167. https:\/\/doi.org\/10.1111\/aogs.13395. (Epub 2018 Jul 24 PMID: 29889977)","journal-title":"Acta Obstet Gynecol Scand"},{"key":"3388_CR52","doi-asserted-by":"publisher","unstructured":"Regidor PA, Schindler AE, Lesoine B, Druckman R (2018) Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm Mol Biol Clin Investig 34(2):\/j\/hmbci.2018.34.issue-2\/hmbci-2017-0067\/hmbci-2017-0067.xml. https:\/\/doi.org\/10.1515\/hmbci-2017-0067. (PMID: 29498933)","DOI":"10.1515\/hmbci-2017-0067"},{"issue":"4","key":"3388_CR53","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00404-019-05064-5","volume":"299","author":"S Pourghasem","year":"2019","unstructured":"Pourghasem S, Bazarganipour F, Taghavi SA, Kutenaee MA (2019) The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole. Arch Gynecol Obstet 299(4):1193\u20131199. https:\/\/doi.org\/10.1007\/s00404-019-05064-5. (Epub 2019 Feb 5 PMID: 30847561)","journal-title":"Arch Gynecol Obstet"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-023-03388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-023-03388-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-023-03388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T03:23:28Z","timestamp":1701487408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-023-03388-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,6]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["3388"],"URL":"https:\/\/doi.org\/10.1007\/s11845-023-03388-5","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,6]]},"assertion":[{"value":"14 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animals or human subjects were used in the current study, only publicly available data was used, and no ethical approval was needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No informed consents were required for the purpose of the current study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}